Intercept Shares May Triple on Liver Drug

Intercept Shares May Triple on Liver Drug Play

Jan. 10 (Bloomberg) -- Intercept price target is raised to $872 from $81 and implies a 216% rally from yesterday’s close of $276, on “heavily positive probability” for OCA to treat nonalcoholic steatohepatitis, Bank of America analyst Rachel McMinn said in note. Olivia Sterns reports on Bloomberg Television's "Money Moves." (Source: Bloomberg)

blog comments powered by Disqus